Loading...
GILD logo
GILD
Gilead Sciences

Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market

Published
08 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$140.00
13.2% undervalued intrinsic discount
06 Aug
US$121.46
Loading
1Y
39.2%
7D
2.7%

Author's Valuation

US$14013.2% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 0.13%

Read more

Shared on30 Apr 25
Fair value Decreased 0.014%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 0.14%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25

Read more